drugset / Trial / NCT07773610
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 2, two-part, multicentre, open label, controlled, randomised clinical trial in adult participants with newly diagnosed, sputum-positive pulmonary drug-sensitive tuberculosis (DSTB). Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis
Timeline
- Start
- 2026-09-25
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BTZ-043 | Small molecule | 1000 mg | — |
| Comparator | Ethambutol | Small molecule | 275 mg | — |
| Subject | Ganfeborole | Small molecule | 20 mg | — |
| Comparator | Isoniazid | Small molecule | 75 mg | — |
| Subject | Linezolid | Other / unclassified | 600 mg | — |
| Comparator | Pyrazinamide | Small molecule | 400 mg | — |
| Subject | Quabodepistat | Small molecule | 30 mg | — |
| Comparator | Rifampicin | Small molecule | 150 mg | — |
| Subject | TBAJ-587 | Small molecule | 100 mg | — |
| Subject | TBAJ-587 | Small molecule | 200 mg | — |
| Subject | Pretomanid | Small molecule | 200 mg | — |